Stocks making the biggest moves premarket: Nvidia, Marvell, Flex and more

Nvidia rose 2.3% after announcing a partnership with SK Hynix for advanced memory tied to its AI factory buildout. Marvell Technology jumped nearly 9% and Flex gained 4% on news they will join the S&P 500, replacing Campbell's and Pool Corp. Nurix Therapeutics surged 24% on a collaboration with Roche to develop and commercialize bexobrutideg, while Micron rebounded 7% and AMD added 2.7% as chip stocks recovered.

Analysis

The clearest second-order read is that AI infrastructure spend is becoming more layered: not just accelerators, but memory, connectivity, and assembly capacity. That broadens the beneficiary set beyond the obvious GPU names and improves the durability of the capex cycle, because shortages can shift pricing power toward whichever component becomes the next bottleneck. In practice, that favors the picks-and-shovels names more than the headline AI leader over the next 1-3 quarters if enterprise spend stays on schedule.

The S&P inclusion move is mechanically bullish but likely more important as a liquidity signal than a fundamental one. Forced index buying can create a short-lived air pocket higher over the next several sessions, but the real question is whether these names can convert passive demand into a sustained multiple re-rate; that usually requires clean execution over the next two earnings prints. For the semiconductor complex, the bounce looks like technical repair after a weak tape rather than a changed earnings regime, so chasing beta here is less attractive than expressing the relative winners with better balance-sheet or content leverage.

The biotech catalyst is different: this is a validation event that can pull the asset closer to pharma-style valuation if the collaboration is perceived as platform-level, not molecule-level. The key risk is that the market overcapitalizes a partnership headline before clinical and regulatory proof, which can unwind fast if early data disappoints over the next 6-12 months. Consensus may be underestimating how much a credible ex-big-pharma partner can shorten financing overhang and expand follow-on deal probability across adjacent protein-degrader platforms.

Key Decisions for Investors

• Go long MRVL vs. short a semis basket (or short QQQ hedge) for 2-6 weeks: the combination of passive inflows plus index inclusion creates a cleaner near-term catalyst than broad AI-beta exposure; target 8-12% relative outperformance, with stop-loss on a failed post-inclusion drift lower.
• Buy NVDA call spreads into the next 1-2 weeks rather than outright stock: the memory-supply angle improves the AI buildout narrative, but upside may be capped near-term by already-rich positioning; use the spread to express upside while limiting theta if the move fades.
• Fade extended MU/AMD strength on any rally extension over the next 3-10 trading days via put spreads: the current bid is technically driven and vulnerable if the broader risk tape softens; risk/reward favors betting on mean reversion rather than a sustained rerating.
• Initiate a tactical long NRIX position with a 3-6 month horizon, but size it as a catalyst trade, not a core hold: collaboration optionality can expand multiples quickly, yet the exit should be tied to confirmation of platform traction or first data readout; downside is binary if the partnership premium compresses.
• Avoid chasing HON on the guidance headline; instead, use it as a relative-value hedge versus more cyclical industrials if you want lower-vol exposure. The upside catalyst is limited unless the spin unlock is followed by clearer aerospace margins, so the better trade is preserving capital rather than paying up for reassurance.